Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • redhot47fla redhot47fla May 7, 2013 4:10 PM Flag

    SGEN 1Q 2013 Results are here:

    Total revenues in the first quarter of 2013 were $57.3 million, compared to $48.2 million in the first quarter of 2012. First quarter 2013 revenues include ADCETRIS net product sales of $33.9 million and ADCETRIS royalty revenues of $2.4 million from international sales of ADCETRIS by Takeda/Millennium. Revenues also reflect amounts earned under the company’s ADCETRIS and ADC collaborations totaling $21.0 million in the first quarter of 2013.

    Research and development expenses for the first quarter of 2013 were $47.7 million, compared to $38.5 million for the first quarter of 2012. This planned increase in 2013 was primarily driven by ADCETRIS expenses, including clinical trials to explore potential additional uses of ADCETRIS and drug supply to Takeda/Millennium under the collaboration. Research and development expenses also include increased investment in the company’s ADC pipeline programs. Selling, general and administrative expenses for the first quarter of 2013 were $21.9 million, compared to $22.2 million for the first quarter of 2012....
    Non-cash, share-based compensation expense for the first quarter of 2013 was $6.6 million, compared to $6.1 million for the first quarter of 2012.

    Net loss for the first quarter of 2013 was $16.3 million, or $0.14 per share, compared to a net loss of $12.3 million, or $0.11 per share, for the first quarter of 2012.

    As of March 31, 2013, Seattle Genetics had $344.1 million in cash, cash equivalents and investments, compared to $364.3 million as of December 31, 2012.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SGEN
47.65-0.17(-0.36%)Jul 2 4:00 PMEDT